Erratum: RGD-fasL induces apoptosis in hepatocellular carcinoma (Cellular and Molecular Immunology (2009) 6: 4 (285-293) DOI: 10.1038/cmi.2009.38);RGD-FasL induces apoptosis in hepatocellular carcinoma

Cellular and Molecular Immunology

Volumn 6, Issue 4, 2009, Pages 285-293

  Liu, Zhongchen ^a   Wang, Juan ^a   Yin, Ping ^a   Qiu, Jinhua ^a   Liu, Ruizhen ^a   Li, Wenzhu ^a   Fan, Xin ^a   Cheng, Xiaofeng ^a   Chen, Caixia ^a   Zhang, Jiakai ^a   Zhuang, Guohong ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Apoptosis; FasL; RGD FasL; Tumor targeting

Indexed keywords

ALANINE AMINOTRANSFERASE; ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID FAS LIGAND FUSION PROTEIN; ASPARTATE AMINOTRANSFERASE; CD61 ANTIGEN; DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; RECOMBINANT FAS LIGAND; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; HYBRID PROTEIN; OLIGOPEPTIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECT; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE; TUMOR VOLUME; CANCER TISSUE; DRUG EFFICACY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER PARENCHYMA; NICK END LABELING; ORGAN INJURY; RECOMBINANT DNA TECHNOLOGY;

ANIMALIA; MURINAE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; FAS LIGAND PROTEIN; GENETIC ENGINEERING; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; TUMOR BURDEN;

EID: 69949134413     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2012.75     Document Type: Erratum

References (24)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674-687. (Pubitemid 44286000)
2. Shen DW, Lu YG, Chin KV, Pastan I, Gottesman MM. Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression. Cell Sci. 1991;98:317-322. (Pubitemid 21924980)
3. Doci R, Bignami P, Bozzetti F, Bonfanti G, Audisio R, Colombo M. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer. 1988;61:1983-1987. (Pubitemid 18123478)
4. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169-1178. (Pubitemid 24006113)
5. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Dukeb RC. A role for CD95 ligand in preventing graft rejection. Nature. 1995;377:630-632.
6. Pinkoski MJ, Green DR. Cloak and dagger in the avoidance of immune surveillance. Curr Opin Gene Dev. 2000;10:114-119.
7. Lienard D, Ewalenko P, Delmotte JJ, Renard N, lejeune FJ. High-dose recombinant tumor necrosis factor α in combination with interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52-60.
8. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996;14:653-2665. (Pubitemid 26329649)
9. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon γ: results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 1996;14:479-489. (Pubitemid 126424027)
10. Alexander HR, Bartlett DL Jr, libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 16:1479-1489,
11. Qin J, Chen D, Hu H, Qiao M, Zhao X, Chen B. Body distributioin of RGD-mediated liposome in brain-targeting drug delivery. Yakugaku Zasshi. 2007;127:1497-1501. (Pubitemid 47360748)
12. Villard V, Kalvuzhniv O, Riccio O, et al. Synthetic RGD containing α-helical coiled coil peptides promote integrin dependent cell adhesion. J Pept Sci. 2006;12:206-212. (Pubitemid 43349361)
13. Wu Pl, Lee SC, Chuang CC, et al. Non-cytotoxic cobra cardiotoxin A5 binds to αvβ3 integrin and inhibits bone resorption. Identification of cardiotoxins as non-RGD integrin binding proteins of the ly-6 family. J Bio Chem. 2006;281:7937-7945.
14. Lu X, Lu D, Scully MF, Kakkar VV. Integrins in drug targeting-RGD templates in toxins. Curr Pharm Des. 2006;12:2749-2769. (Pubitemid 44184634)
15. Kuroda K, Miyata K, Shikama H, et al. Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice. Int J Cancer. 1995;63:152-157.
16. Shikama H, Miyata K, Sakae N, et al. A novel mutein of TNFα containing the Arg-Gly-Aspsequence shows reduced toxicity in intestine. Mediators Inammation. 1994;3:111-116. (Pubitemid 24131926)
17. Miyata K, Mitsuishi Y, Shikama H, et al. Overcoming the metastasis-enhancing potential of human tumor necrosis factor α by introducing the cell-adhesive Arg-Gly-Asp sequence. Interferon Cytokine Res. 1995;15:161-169.
18. Shikama H, Miyata K, Sakae N, et al. Novel mutein of tumor necrosis factor α (F4614) with reduced hypotensive effect. Interferon Cytokine Res. 1995;15:677-684.
19. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005;23:1418-1423. (Pubitemid 41679395)
20. Shukla R, Thomas TP, Peters J, Kotlyar A, Myc A, Baker JR. Tumorangiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem Commun (Camb) 2005; 5739-5741. (Pubitemid 43028741)
21. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mousemodel. Science. 1998;279:377-380. (Pubitemid 28063372)
22. Pasqualini R, Koivunen E, Ruoslahti E. αV integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997;15:542-546. (Pubitemid 27251571)
23. Adamson GM, Billings RE. Tumor necrosis factor: receptor binding and expression of receptors in cultured mouse hepatocytes. Pharmacol Exp Ther. 1994;269:367-373.
24. Koivunen E, Gay DA, Ruoslahti E. Selection of peptides binding to the a5h1 integrin from phage display library. Biol Chem. 1993;268:20205-20210.